Clinical trials: COVID
SARS-COV2 Infection
COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey
Study of COVID-19 seroprevalence in precarious population living in shelters of Samusocial de Paris and in staff working in these centers during COVID-19 epidemic.
- Trial name
- NCT04470648
- Testing
- blood test for SARS-COV2 serology
- Where
- 3 sites in France
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
SARS-CoV-2 Infection
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects.
- Trial name
- NCT05017168
- Testing
- CT-P63
- Where
- Poland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celltrion
Covid19
USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19
Estimation of the prevalence and contagiousness of undocumented novel coronavirus infections is critical for understanding the overall prevalence and pandemic potential of this disease.
- Trial name
- IVERCAR (NCT04425850)
- Testing
- Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)
- Where
- Argentina
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- Eurnekian Public Hospital
Covid19
Prevalence of COVID-19 Antibodies Kingman AZ
The COVID-19 disease outbreak is a historic event that has challenged medical systems in the United States. Currently, most reports of confirmed cases rely on the testing of symptomatic patients.
- Trial name
- NCT04533360
- Testing
- VITROS Anti-SARS-CoV-2 IgG test
- Where
- United States
- Volunteers
- 566 people, healthy volunteers welcome
- Sponsor
- Kingman Regional Medical Center
COVID-19
Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)
This is a phase I, randomized, placebo-controlled, double-blind study, to evaluate safety and immunogenicity of a recombinant SARS-CoV-2 vaccine (CHO cell) in Chinese healthy population aged 18 years and older.
- Trial name
- NCT04636333
- Testing
- Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28, Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
- Where
- China
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Patient Safety
Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study
The COVID-19 epidemic is causing a global health crisis. In France, it has imposed a major reorganization of the healthcare system. This emergency reorganization is unprecedented. It involved first, second and third line care.
- Trial name
- PSI-RECORd-XP (NCT04348552)
- Testing
- Primary care professionals reports of potential patient safety incidents, non-COVID-19 related
- Where
- France
- Volunteers
- healthy volunteers welcome
- Sponsor
- Nantes University Hospital
SARS-CoV-2 Infection, COVID-19
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children
This is a Phase 1/2/3 study in healthy children. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and…
- Trial name
- NCT04816643
- Testing
- Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg
- Where
- 128 sites in United States, Brazil and 4 more
- Volunteers
- 11,837 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Healthy Adults
An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines.
The SOLVE-01 trial is a study evaluating four SARS-CoV-2 vaccines as booster injections: two experimental vaccines (CD40.RBDv and CD40.Pan.CoV, both combined with the Hiltonol® adjuvant) and two authorised vaccines (Comirnaty®…
- Trial name
- SOLVE-01 (NCT07605520)
- Testing
- CD40.RBDv vaccine adjuvanted with Hiltonol®, CD40.Pan.CoV vaccine adjuvanted with Hiltonol®, Comirnaty® vaccine
- Where
- 3 sites in France, Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Severe Acute Respiratory Syndrome, Coronavirus
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
- Conditions
- Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2, COVID-19
- Trial name
- NCT04449276
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- CureVac
Sars-CoV2, Infection Viral
HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers
Background: Aim: To demonstrate the efficacy of low-dose hydroxychloroquine as primary prevention in healthcare workers Design, participants and interventions: Prospective, randomized, parallel group, double-blinded, placebo…
- Conditions
- Sars-CoV2, Infection Viral, Healthcare Worker, Prophylaxis
- Trial name
- NCT04336748
- Testing
- Hydroxychloroquine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical University of Vienna
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
- Trial name
- NCT05375838
- Testing
- mRNA-1073, mRNA-1010, mRNA-1273
- Where
- 14 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19
This study is a randomized, double-blinded, and placebo-controlled phase Ia/IIa clinical trial of the Inactivated SARS-CoV-2 Vaccine to evaluate the safety and immunogenicity of the vaccine in healthy people aged 18~59 Years.
- Trial name
- NCT04412538
- Testing
- Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule, Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule, Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
- Where
- China
- Volunteers
- 942 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)
The goal of this open-label clinical trial is to evaluate the safety and immunogenicity of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster in Adult Subjects in Indonesia.
- Conditions
- COVID-19 Pandemic, COVID-19 Vaccines, COVID-19 Virus Disease
- Trial name
- NCT06259578
- Testing
- INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
- Where
- Indonesia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
Heathly Subjects Susceptible to SARS-CoV-2 Infection
Microbiome-Based Risk Prediction of SARS-CoV-2 in Children and Families (PREDICOL)
The goal of this observational cohort study is to evaluate the association between gut microbiota composition, dietary patterns, lifestyle-related factors, and neurodevelopmental outcomes, as well as susceptibility to SARS-CoV-2…
- Trial name
- PREDICOL (NCT07717008)
- Where
- Spain
- Volunteers
- 932 people, healthy volunteers welcome
- Sponsor
- Spanish National Research Council
COVID-19
Breath Samples Collection Clinical Trial, for Development of the TERA BioStation T101, Intended for CoV-19 Exhalation Products Detection.
The Sponsor has developed a rapid screening tool intended to determine if the subject tested has COVID-19.
- Trial name
- NCT05162495
- Testing
- BioStation T101 and TeraTube
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tera Group
SARS-CoV-2, Coronavirus
Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary
The additional effect of personalized health education compared to general education following the internationally accepted principles will be evaluated in the prevention of the serious course of the novel coronavirus infection.
- Conditions
- SARS-CoV-2, Coronavirus, COVID-19, 2019-nCoV
- Trial name
- PROACTIVE-19 (NCT04321928)
- Testing
- Personalized health education, General health education
- Where
- Hungary
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- University of Pecs
Covid19
COvid Pandemic Institutional maNaGement
Covid-19 has increased organizational tensions within health services (lack of resources, difficulties in recruiting healthcare professionals , elderly and polypathological patients, etc.) and tested the reliability of health…
- Trial name
- COPING (NCT04908007)
- Testing
- Qualitative analysis for professionals, Quantitative analysis for Professionals, Quantitative analysis for Patients
- Where
- 4 sites in France
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Healthy Adult Volunteers
Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination
The investigators conduct a prospective analysis to compare homologous and heterologous adenovirus vector ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine inoculation.
- Trial name
- NCT05074368
- Testing
- ChAdOx1-nCov-19 (Astra-Zeneca), SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
- Where
- Taiwan
- Volunteers
- 499 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
COVID19
SARS-CoV-2 (COVID-19) Detection Using the Breath Analizer TeraSystem
The purpose of the study is to verify the sensibility and accuracy of a rapid detection test for SARS-CoV-2 in breath samples analyzed by the breath detector analyzer TeraSystem, comparing with PCR tests.
- Trial name
- NCT04497610
- Testing
- Breath sample
- Where
- Costa Rica
- Volunteers
- healthy volunteers welcome
- Sponsor
- Instituto Costarricense de Investigaciones Clínicas ICIC
COVID-19 Pandemic
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the safety and immunogenicity of SCTV01E in population of different ages who have been vaccinated against COVID-19.
- Trial name
- SCTV01E (NCT05652543)
- Testing
- SCTV01E
- Where
- 4 sites in China
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.